-
Je něco špatně v tomto záznamu ?
SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors
M. Dvorakova, A. Kubik-Zahorodna, A. Straiker, R. Sedlacek, A. Hajkova, K. Mackie, J. Blahos
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, Research Support, N.I.H., Extramural, práce podpořená grantem
Grantová podpora
RVO 68378050
Czech Academy of Sciences
GACR 19-24172S
Grant Agency of Czech Republic
CZ.1.05/2.1.00/19.0395
Ministry of Education, Youth and Sports of the Czech Republic; 'Higher quality and capacity for transgenic models'
P01 DA009158
NIDA NIH HHS - United States
LM2015040
Czech Centre for Phenogenomics
NLK
Free Medical Journals
od 1968 do Před 1 rokem
Europe PubMed Central
od 1968 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2002-01-01 do Před 1 rokem
Wiley Free Content
od 1997 do Před 1 rokem
PubMed
33491188
DOI
10.1111/bph.15383
Knihovny.cz E-zdroje
- MeSH
- adaptorové proteiny signální transdukční fyziologie MeSH
- afekt MeSH
- emoce MeSH
- extinkce (psychologie) MeSH
- kanabinoidy MeSH
- myši knockoutované MeSH
- myši MeSH
- nocicepce * MeSH
- receptor kanabinoidní CB1 * genetika MeSH
- receptory kanabinoidní MeSH
- strach MeSH
- zvířata MeSH
- Check Tag
- mužské pohlaví MeSH
- myši MeSH
- ženské pohlaví MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Research Support, N.I.H., Extramural MeSH
BACKGROUND AND PURPOSE: Src homology 3-domain growth factor receptor-bound 2-like endophilin interacting protein 1 (SGIP1) interacts with cannabinoid CB1 receptors. SGIP1 is abundantly and principally expressed within the nervous system. SGIP1 and CB1 receptors co-localize in axons and presynaptic boutons. SGIP1 interferes with the internalization of activated CB1 receptors in transfected heterologous cells. Consequently, the transient association of CB1 receptors with β-arrestin2 is enhanced and prolonged, and CB1 receptor-mediated ERK1/2 signalling is decreased. Because of these actions, SGIP1 may modulate affect, anxiety, pain processing, and other physiological processes controlled by the endocannabinoid system (ECS). EXPERIMENTAL APPROACH: Using a battery of behavioural tests, we investigated the consequences of SGIP1 deletion in tasks regulated by the ECS in SGIP1 constitutive knockout (SGIP1-/- ) mice. KEY RESULTS: In SGIP1-/- mice, sensorimotor gating, exploratory levels, and working memory are unaltered. SGIP1-/- mice have decreased anxiety-like behaviours. Fear extinction to tone is facilitated in SGIP1-/- females. Several cannabinoid tetrad behaviours are altered in the absence of SGIP1. SGIP1-/- males exhibit abnormal behaviours on Δ9 -tetrahydrocannabinol withdrawal. SGIP1 deletion also reduces acute nociception, and SGIP1-/- mice are more sensitive to analgesics. CONCLUSION AND IMPLICATIONS: SGIP1 was detected as a novel protein associated with CB1 receptors, and profoundly modified CB1 receptor signalling. Genetic deletion of SGIP1 particularly affected behavioural tests of mood-related assessment and the cannabinoid tetrad. SGIP1-/- mice exhibit decreased nociception and augmented responses to CB1 receptor agonists and morphine. These in vivo findings suggest that SGIP1 is a novel modulator of CB1 receptor-mediated behaviour.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21025877
- 003
- CZ-PrNML
- 005
- 20211026133424.0
- 007
- ta
- 008
- 211013s2021 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/bph.15383 $2 doi
- 035 __
- $a (PubMed)33491188
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dvorakova, Michaela $u Department of Molecular Pharmacology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, Czech Republic $u Department of Psychological and Brain Sciences, Gill Center for Molecular Bioscience, Indiana University, Bloomington, Indiana, USA
- 245 10
- $a SGIP1 is involved in regulation of emotionality, mood, and nociception and modulates in vivo signalling of cannabinoid CB1 receptors / $c M. Dvorakova, A. Kubik-Zahorodna, A. Straiker, R. Sedlacek, A. Hajkova, K. Mackie, J. Blahos
- 520 9_
- $a BACKGROUND AND PURPOSE: Src homology 3-domain growth factor receptor-bound 2-like endophilin interacting protein 1 (SGIP1) interacts with cannabinoid CB1 receptors. SGIP1 is abundantly and principally expressed within the nervous system. SGIP1 and CB1 receptors co-localize in axons and presynaptic boutons. SGIP1 interferes with the internalization of activated CB1 receptors in transfected heterologous cells. Consequently, the transient association of CB1 receptors with β-arrestin2 is enhanced and prolonged, and CB1 receptor-mediated ERK1/2 signalling is decreased. Because of these actions, SGIP1 may modulate affect, anxiety, pain processing, and other physiological processes controlled by the endocannabinoid system (ECS). EXPERIMENTAL APPROACH: Using a battery of behavioural tests, we investigated the consequences of SGIP1 deletion in tasks regulated by the ECS in SGIP1 constitutive knockout (SGIP1-/- ) mice. KEY RESULTS: In SGIP1-/- mice, sensorimotor gating, exploratory levels, and working memory are unaltered. SGIP1-/- mice have decreased anxiety-like behaviours. Fear extinction to tone is facilitated in SGIP1-/- females. Several cannabinoid tetrad behaviours are altered in the absence of SGIP1. SGIP1-/- males exhibit abnormal behaviours on Δ9 -tetrahydrocannabinol withdrawal. SGIP1 deletion also reduces acute nociception, and SGIP1-/- mice are more sensitive to analgesics. CONCLUSION AND IMPLICATIONS: SGIP1 was detected as a novel protein associated with CB1 receptors, and profoundly modified CB1 receptor signalling. Genetic deletion of SGIP1 particularly affected behavioural tests of mood-related assessment and the cannabinoid tetrad. SGIP1-/- mice exhibit decreased nociception and augmented responses to CB1 receptor agonists and morphine. These in vivo findings suggest that SGIP1 is a novel modulator of CB1 receptor-mediated behaviour.
- 650 _2
- $a adaptorové proteiny signální transdukční $x fyziologie $7 D048868
- 650 _2
- $a afekt $7 D000339
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kanabinoidy $7 D002186
- 650 _2
- $a emoce $7 D004644
- 650 _2
- $a extinkce (psychologie) $7 D005108
- 650 _2
- $a strach $7 D005239
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši knockoutované $7 D018345
- 650 12
- $a nocicepce $7 D059225
- 650 12
- $a receptor kanabinoidní CB1 $x genetika $7 D043884
- 650 _2
- $a receptory kanabinoidní $7 D043882
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a Research Support, N.I.H., Extramural $7 D052061
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kubik-Zahorodna, Agnieszka $u The Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
- 700 1_
- $a Straiker, Alex $u Department of Psychological and Brain Sciences, Gill Center for Molecular Bioscience, Indiana University, Bloomington, Indiana, USA
- 700 1_
- $a Sedlacek, Radislav $u The Czech Center for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic
- 700 1_
- $a Hajkova, Alena $u Department of Molecular Pharmacology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, Czech Republic
- 700 1_
- $a Mackie, Ken $u Department of Psychological and Brain Sciences, Gill Center for Molecular Bioscience, Indiana University, Bloomington, Indiana, USA
- 700 1_
- $a Blahos, Jaroslav $u Department of Molecular Pharmacology, Institute of Molecular Genetics of the Czech Academy of Sciences, Prague 4, Czech Republic
- 773 0_
- $w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 178, č. 7 (2021), s. 1588-1604
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33491188 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20211013 $b ABA008
- 991 __
- $a 20211026133430 $b ABA008
- 999 __
- $a ok $b bmc $g 1714780 $s 1146384
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 178 $c 7 $d 1588-1604 $e 20210227 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
- GRA __
- $a RVO 68378050 $p Czech Academy of Sciences
- GRA __
- $a GACR 19-24172S $p Grant Agency of Czech Republic
- GRA __
- $a CZ.1.05/2.1.00/19.0395 $p Ministry of Education, Youth and Sports of the Czech Republic; 'Higher quality and capacity for transgenic models'
- GRA __
- $a P01 DA009158 $p NIDA NIH HHS $2 United States
- GRA __
- $a LM2015040 $p Czech Centre for Phenogenomics
- LZP __
- $a Pubmed-20211013